Porownywarka

Matrixyl 3000 vs GHK-Cu side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

Matrixyl 3000GHK-Cu

Udostępnij porównanie peptydów

Wlasciwosc	Matrixyl 3000	GHK-Cu
Kategoria	Skóra i włosy	Skóra i włosy
Znany tez jako	Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7, Pal-GHK, Pal-GQPR	Copper Peptide, Glycyl-L-histidyl-L-lysine copper
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Cosmetic use - Widely available Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Used in cosmetic products with limited human topical-skincare evidence; the source also notes injectable compounding restrictions and a pending reclassification process. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Advanced anti-aging, collagen synthesis, skin repair	Skin rejuvenation, wound healing, hair growth, anti-aging
Jak dziala	Matrixyl 3000 is presented as a palmitoylated matrikine complex. Palmitoyl tripeptide-1 is reported to signal fibroblasts toward production of extracellular-matrix proteins including collagen, elastin, and fibronectin. Palmitoyl tetrapeptide-7 is described as acting on inflammatory signaling by reducing IL-6, a cytokine associated in the source with age-related matrix degradation and possible collagen glycation damage. The lipid attachments are included to help the otherwise water-soluble peptides pass into the skin when applied topically.	GHK-Cu is described as the copper(II) complex of the GHK tripeptide. The source connects its activity to copper binding and possible cellular copper delivery, but also emphasizes effects that go beyond a simple carrier model. Reported laboratory observations include shifts in gene expression, increased fibroblast production of extracellular-matrix components, keratinocyte support, vascular-related activity, and antioxidant or anti-inflammatory signals. The precise mechanism is still not fully defined.
Typowe dawkowanie	Limited community data available · See research protocols	1-2 mg daily injection or 0.05% topical · Once daily · Subcutaneous injection or topical application
Dawkowanie z badań	2-8% in formulations · Ongoing use for maintained effects · Topical (serums, creams)	1-2 mg for injectable protocols · Varies by application · Subcutaneous injection or topical application
Typowy czas trwania	Ongoing use for maintained effects	Varies by application
Podanie	Topical (serums, creams)	Subcutaneous injection or topical application
Timing	Morning or as directed With or without food	Evening for skin or recovery contexts With or without food
Poziom dowodów	Badawcze	Badania kliniczne
Mozliwe skutki uboczne	Generally very well-tolerated (Reported as generally well tolerated in the source.) Temporary stinging (Reported during the first week.) May trigger breakouts in acne-prone skin (Listed as a possible response for acne-prone skin.) +1 więcej Avoid mixing with strong acids (Source-supported topical compatibility caution.)	Generally well tolerated (Reported as a general tolerability statement in the source.) Mild topical irritation, redness, or tingling (Associated with topical use.) Injection-site reactions (Associated with injectable use.) +4 więcej Possible histamine release (Source advises caution for MCAS or histamine sensitivity.) Copper toxicity risk with excessive use (Risk described for excessive exposure.) Wilson's disease contraindication (Source lists Wilson's disease as contraindicated.) Caution with active cancer (Source flags an angiogenesis-related concern.)
Podsumowanie researchu	The supplied research summary describes Matrixyl 3000 as biologically plausible, with in vitro findings for its components that include fibroblast proliferation, synthesis of collagen types I, III, IV, and VII, and IL-6 reduction by the tetrapeptide. It also cautions that commonly cited 12-week reports for wrinkles and skin laxity are largely manufacturer-originated or sponsored, while large independent placebo-controlled studies focused on this exact complex are described as sparse. The source states that stronger independent evidence in this peptide family is associated with the original Pal-KTTKS Matrixyl data. The expected area of interest is skin texture and firmness rather than muscle-relaxing effects.	The source describes a mixed evidence base. Cell and animal work is reported for wound repair, collagen deposition, fibroblast activity, elastin and growth-factor production, keratinocyte protection, and lung-injury models. Human data are described as small topical cosmetic studies, including facial-cream and eye-cream studies with 71 and 41 participants that reported changes in skin density, thickness, and wrinkle appearance. These data are encouraging for topical skin endpoints but do not establish injected or systemic benefits.
Referencje	Źródło Źródło +1 więcej Źródło	PubMed PubMed +1 więcej PubMed
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Matrixyl 3000

GHK-Cu

Kategoria

Skóra i włosy

Znany tez jako

Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7, Pal-GHK, Pal-GQPR

Copper Peptide, Glycyl-L-histidyl-L-lysine copper

Zatwierdzony przez FDA

Nie

Status kliniczny

Cosmetic use - Widely available

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Used in cosmetic products with limited human topical-skincare evidence; the source also notes injectable compounding restrictions and a pending reclassification process.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Advanced anti-aging, collagen synthesis, skin repair

Skin rejuvenation, wound healing, hair growth, anti-aging

Jak dziala

Matrixyl 3000 is presented as a palmitoylated matrikine complex. Palmitoyl tripeptide-1 is reported to signal fibroblasts toward production of extracellular-matrix proteins including collagen, elastin, and fibronectin. Palmitoyl tetrapeptide-7 is described as acting on inflammatory signaling by reducing IL-6, a cytokine associated in the source with age-related matrix degradation and possible collagen glycation damage. The lipid attachments are included to help the otherwise water-soluble peptides pass into the skin when applied topically.

GHK-Cu is described as the copper(II) complex of the GHK tripeptide. The source connects its activity to copper binding and possible cellular copper delivery, but also emphasizes effects that go beyond a simple carrier model. Reported laboratory observations include shifts in gene expression, increased fibroblast production of extracellular-matrix components, keratinocyte support, vascular-related activity, and antioxidant or anti-inflammatory signals. The precise mechanism is still not fully defined.

Typowe dawkowanie

Limited community data available · See research protocols

1-2 mg daily injection or 0.05% topical · Once daily · Subcutaneous injection or topical application

Dawkowanie z badań

2-8% in formulations · Ongoing use for maintained effects · Topical (serums, creams)

1-2 mg for injectable protocols · Varies by application · Subcutaneous injection or topical application

Typowy czas trwania

Ongoing use for maintained effects

Varies by application

Podanie

Topical (serums, creams)

Subcutaneous injection or topical application

Timing

Morning or as directed

With or without food

Evening for skin or recovery contexts

With or without food

Poziom dowodów

Badawcze

Badania kliniczne

Mozliwe skutki uboczne

Generally very well-tolerated (Reported as generally well tolerated in the source.)
Temporary stinging (Reported during the first week.)
May trigger breakouts in acne-prone skin (Listed as a possible response for acne-prone skin.)

+1 więcej

Avoid mixing with strong acids (Source-supported topical compatibility caution.)

Generally well tolerated (Reported as a general tolerability statement in the source.)
Mild topical irritation, redness, or tingling (Associated with topical use.)
Injection-site reactions (Associated with injectable use.)

+4 więcej

Possible histamine release (Source advises caution for MCAS or histamine sensitivity.)
Copper toxicity risk with excessive use (Risk described for excessive exposure.)
Wilson's disease contraindication (Source lists Wilson's disease as contraindicated.)
Caution with active cancer (Source flags an angiogenesis-related concern.)

Podsumowanie researchu

The supplied research summary describes Matrixyl 3000 as biologically plausible, with in vitro findings for its components that include fibroblast proliferation, synthesis of collagen types I, III, IV, and VII, and IL-6 reduction by the tetrapeptide. It also cautions that commonly cited 12-week reports for wrinkles and skin laxity are largely manufacturer-originated or sponsored, while large independent placebo-controlled studies focused on this exact complex are described as sparse. The source states that stronger independent evidence in this peptide family is associated with the original Pal-KTTKS Matrixyl data. The expected area of interest is skin texture and firmness rather than muscle-relaxing effects.

The source describes a mixed evidence base. Cell and animal work is reported for wound repair, collagen deposition, fibroblast activity, elastin and growth-factor production, keratinocyte protection, and lung-injury models. Human data are described as small topical cosmetic studies, including facial-cream and eye-cream studies with 71 and 41 participants that reported changes in skin density, thickness, and wrinkle appearance. These data are encouraging for topical skin endpoints but do not establish injected or systemic benefits.

Referencje

+1 więcej

+1 więcej

Pełny profil